ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/SMO
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/SMO
8
trial(s) found.
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
Itraconazole
Pumitamig
SMO inhibitor
bispecific PD-L1/VEGFA antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,SMO-targeting
cancer therapy,VEGFA-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGFA-targeting
+ SMO inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
+ SMO inhibitor
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
+ SMO inhibitor
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05914116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors (
DB-1311-O-1001
)
anti-B7H3 antibody-drug conjugate
+ SMO inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05150691
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (
DB-1303-O-1001
)
anti-ERBB2 antibody-drug conjugate
+ SMO inhibitor
HER2-positive solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12618001351202
Curative
Not Applicable
Not yet recruiting
A prospective case series evaluating neo-adjuvant use of Vismodegib in patients with periocular basal cell carcinoma to evaluate reduction in clinical and surgical tumour margins
SMO inhibitor,first generation
Cancer
Cutaneous basal cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12623000652673
Advanced
Phase 1
Withdrawn
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELVN-002 in Healthy Adult Volunteers: Part C Open-label Drug-Drug Interaction (
ELVN-002-002
)
ERBB2 inhibitor,exon 20 selective
+ SMO inhibitor
Non-small cell lung cancer
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6027 - Joondalup - Joondalup Health Campus
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ SMO inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Withdrawn (1)
Status unknown (1)
Recruitment Country and State
NSW (5)
QLD (4)
SA (3)
VIC (3)
WA (3)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (3)
Trial Type
Advanced (7)
Curative (1)
Cancer Therapy Class
SMO
100%
PD-1/PD-L1
25%
MET
25%
ERBB2
25%
PD-L1
13%
VEGFA
13%
FR-alpha
13%
PD-1
13%
VEGF
13%
AR
13%
B7H3
13%
CYP17A1
13%
androgen axis
13%
ALK
13%
ATR
13%
BCR-ABL1
13%
CDK4
13%
CDK6
13%
CRAF
13%
EGFR
13%
FLT3
13%
JAK1
13%
JAK2
13%
KIT
13%
PDGFR
13%
PDGFRA
13%
PI3K
13%
RAF
13%
ROS1
13%
SRC
13%
VEGFR
13%
YES1
13%
mTOR
13%
mTORC1
13%
mTORC2
13%
Facility
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2109 - North Ryde - Macquarie University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4215 - Southport - Tasman Oncology (1)
6009 - Nedlands - One Clinical Research (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
6027 - Joondalup - Joondalup Health Campus (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Breast adenocarcinoma
Breast cancer
Gastrointestinal cancer
Gynaecological cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
Head and neck cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Viral-related cancer
Biliary tract cancer
Epithelial Ovarian Cancer
Exocrine pancreatic cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal cancer
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
HER2-positive solid tumour
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy